Pan-cancer analyses indicate that patients with higher GBP1 expression are more likely to exhibit “hot” anti-tumor immune phenotypes, characterized by lower Tumor Immune Dysfunction and Exclusion (TIDE) scores and higher immunophenoscores, suggesting a greater likelihood of responding to immunotherapy [69]. This evidence concerns the gene GBP1 and neoplasm.